Page 13 - 《中国药房》2021年21期

ABSTRACT OBJECTIVE：To provide reference for further promoting the high-quality development of the biomedical industry in
Guangdong-Hong Kong-Macao Greater Bay Area. METHODS：Through summarizing the development status and development
environment of the biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area，the construction experience of
foreign advanced biomedical industrial park was introduced，and the problems and challenges faced by the biomedical industry in
the Guangdong-Hong Kong-Macao Greater Bay Area were sorted out so as to put forward relevant countermeasures and
suggestions. RESULTS & CONCLUSIONS： Guangdong-Hong Kong-Macao Greater Bay Area has received multiple policy
support，which is conducive to the development of biomedical industry. The industrial chain is complete，and the scale advantage
of biological industry is showing day by day. Biological industry has achieved fruitful innovation achievement，and its R&D
investment is in the leading position in the country. The pharmaceutical manufacturing industry is developed and the total amount of
medical resources is large. The financial advantages are obvious，and institutional innovation is conducive to the development of
biomedical industry. The process of internationalization takes the leading place，which is conducive to continuously promoting
foreign cooperation. However， compared with foreign advanced biomedical industrial parks， Guangdong-Hong Kong-Macao
Greater Bay Area still has some deficiencies in management mode，service mode and“industry-university-institute”cooperation. It
also faces the following problems that the legal systems and industry norms of the three places need to be further connected；there
is a talent gap；the industrial chain is not perfect；the support for new drug R&D is insufficient；the“industry-university-institute”
cooperation needs to be strengthened；the level of financial support needs to be improved. Accordingly，it is recommended to break
down institutional barriers，and promote the connection between the legal system and industry norms；innovate talent policies，and
continue to attract excellent R&D talents；introduce leading companies，and improve the industrial chain；open up clinical trial
channels and promote the transformation efficiency of scientific research achievements；strengthen“industry-university-institute”
cooperation，and promote the improvement of biomedical innovation ability；make good use of financial support to help the rapid
rise of biomedical industry enterprises，so as to promote the high-quality development of biomedical industry in Guangdong-Hong
Kong-Macao Greater Bay Area.
KEYWORDS Guangdong-Hong Kong-Macao Greater Bay Area；Biomedical industry；Development；Suggestion

生物医药产业是关系国计民生的重要产业。2015 澳大湾区发展规划纲要》明确指出，“要支持港深创新及
年，国务院发布《国务院关于印发<中国制造 2025>的通 科技园、中新广州知识城、南沙庆盛科技创新产业基地、
知》，随后，国家发展改革委、工业和信息化部、科技部等 横琴粤澳合作中医药科技产业园等重大创新载体建
多部门陆续发布《国家发展改革委公布<战略性新兴产 设。……推动优质医疗卫生资源紧密合作，支持港澳医
业重点产品和服务指导目录>2016版》《六部门关于印发 疗卫生服务提供主体在珠三角九市按规定以独资、合资
<医药工业发展规划指南>的通知》等文件，明确提出将 或合作等方式设置医疗机构，发展区域医疗联合体和区
生物医药产业纳入国家重点发展的高端产业领域 [1－3] 。 [4]
域性医疗中心”。2020 年 9 月，国家市场监管总局、国
粤港澳大湾区是我国生物医药产业聚集的重要区域，其
家药监局等8部门联合发布《粤港澳大湾区药品医疗器
产业基础完备、实力领先、成就突出，拥有广州、深圳等
械监管创新发展工作方案》 ，为打造粤港澳大湾区医
[5]
生物医药发展重点城市，以及广州开发区、深圳高新区
药产业高水平科技创新平台、实现产业深度融合和升
等多个全国领先的生物医药产业园区。近年来，在众多
级，注入了一剂政策的“强心针”。
利好政策的不断支持下，粤港澳大湾区生物医药产业发
而后，广东省接连发布了《广东省人民政府办公厅
展迅速，但仍存在一些制约产业进一步发展的问题亟待
关于印发广东省促进医药产业健康发展实施方案的通
解决。为此，笔者梳理了粤港澳大湾区生物医药产业发
知》《关于促进生物医药创新发展的若干政策措施的通
展现状及发展环境，对比国外先进生物医药产业园区建
设经验，归纳总结粤港澳大湾区现存的问题，并进一步 知》等文件，支持围绕医药领域重点方向、关键技术，加
提出相关对策和建议，以期助力粤港澳大湾区生物医药 快推进中试中心、企业技术中心、工程实验室、工程研究
产业持续高质量发展。 中心等创新平台建设；加快布局建设生命科学、高端医
1 粤港澳大湾区生物医药产业发展现状环境 疗、健康安全、海洋药物等产业；支持各城市明确功能定
1.1 多重政策支持，为生物医药产业发展保驾护航 位、错位发展 [6－7] 。此外，粤港澳大湾区内各个城市也纷
政策支持是促进产业发展的推动器。生物医药产 纷出台了政策文件，积极规划并推动生物医药产业发
业作为粤港澳大湾区的重点扶持产业之一，具有良好的 展。粤港澳大湾区生物医药产业涉及的主要政策如表1
政策发展优势。2019年，中共中央、国务院印发的《粤港 所示。

中国药房 2021年第32卷第21期 China Pharmacy 2021 Vol. 32 No. 21 ·2567 ·